{"DataElement":{"publicId":"7353109","version":"1","preferredName":"Category for Concomitant Medication","preferredDefinition":"A grouping of topic-variable values based on sponsor defined characteristics.","longName":"CMCAT_SPD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6400384","version":"1","preferredName":"Concomitant Medication Domain Concomitant Medication Category","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to concomitant medication administration._A classification of concomitant medication data.","longName":"4550855v1.0:6400382v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"4550855","version":"1","preferredName":"Concomitant Medication Domain","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to concomitant medication administration.","longName":"C49568","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant Medication Domain","conceptCode":"C49568","definition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to concomitant medication administration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06047D53-A3ED-FF3E-E050-BB89AD430B5B","latestVersionIndicator":"Yes","beginDate":"2014-10-22","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-10-22","modifiedBy":"ONEDATA","dateModified":"2014-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6400382","version":"1","preferredName":"Concomitant Medication Category","preferredDefinition":"A classification of concomitant medication data.","longName":"C83218","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant Medication Category","conceptCode":"C83218","definition":"A classification of concomitant medication data.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7369ABB9-B62E-44AD-E053-F662850A110C","latestVersionIndicator":"Yes","beginDate":"2018-08-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-14","modifiedBy":"ONEDATA","dateModified":"2018-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CDISC:Clinical Data Interchange Standards Consortium","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"7369ABB9-B63F-44AD-E053-F662850A110C","latestVersionIndicator":"Yes","beginDate":"2018-08-14","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-14","modifiedBy":"KUMMEROA","dateModified":"2021-06-09","changeDescription":"Elevated to Standard per governance approval by RA. 2021-6-9 ak. 1/4/19 tmt released/usage. created for CDASH 8/14/18 LS","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7353106","version":"1","preferredName":"Concomitant Medication Category Clinical Study Sponsor Defined Category","preferredDefinition":"A classification of concomitant medication data._An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]_Clearly characterized or delimited._A grouping of items based on some commonality or by user defined characteristics.","longName":"CMCAT_SPD","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"RADIATION","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2567129","version":"1","preferredName":"Radiation Therapy","longName":"2567129","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D346-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-21","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-10-21","modifiedBy":"KUMMEROA","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C1AD-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"STEM CELL","valueDescription":"Stem Cell Therapy","ValueMeaning":{"publicId":"7353108","version":"1","preferredName":"Stem Cell Therapy","longName":"7353108","preferredDefinition":"A treatment modality that leverages stem cells to prevent or treat disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stem Cell Therapy","conceptCode":"C165194","definition":"A treatment modality that leverages stem cells to prevent or treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA84C6A7-C1BB-382E-E053-4EBD850A5A7D","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C1D6-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"VACCINE THERAPY","valueDescription":"Vaccine Therapy","ValueMeaning":{"publicId":"2568332","version":"1","preferredName":"Vaccine Therapy","longName":"2568332","preferredDefinition":"Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vaccine Therapy","conceptCode":"C15347","definition":"Immunotherapy using a preparation that usually contains a complex mixture of disease-related antigens, immunopotentiating agents, and immunomodulators, which stimulate the immune system to destroy pathogenic microorganisms or tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D7F9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-02","modifiedBy":"REEVESD","dateModified":"2009-09-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C1E1-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"ANTISENSE THERAPY","valueDescription":"Antisense Therapy","ValueMeaning":{"publicId":"2571539","version":"1","preferredName":"Antisense Therapy","longName":"2571539","preferredDefinition":"Antisense Oligonucleotide Therapy","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antisense Therapy","conceptCode":"C16236","definition":"Treatment using nucleic acid oligomers to bind to specific mRNA to deter protein production and alter disease process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E480-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-08-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-08-13","modifiedBy":"CURTIST","dateModified":"2007-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C1ED-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"ONCOLYTIC VIROTHERAPY","valueDescription":"Oncolytic Virotherapy","ValueMeaning":{"publicId":"2563827","version":"1","preferredName":"Oncolytic Virotherapy","longName":"2563827","preferredDefinition":"Treatment using an oncolytic virus (a virus that infects and breaks down cancer cells but not normal cells). Oncolytic virus therapy may make it easier to kill tumor cells with chemotherapy and radiation therapy. It is a type of targeted therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncolytic Virus Therapy","conceptCode":"C62713","definition":"A targeted therapy that uses viral infection to cause the lysis of tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C660-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-12-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-23","modifiedBy":"REEVESD","dateModified":"2014-10-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C1F8-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"ANTI-RETROVIRAL THERAPY","valueDescription":"Antiretroviral Therapy","ValueMeaning":{"publicId":"2738677","version":"1","preferredName":"Antiretroviral Therapy","longName":"2738677","preferredDefinition":"Treatment of retroviral infections with medications that target the virus directly, limiting the ability of infected cells to produce new virus particles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiretroviral Therapy","conceptCode":"C94631","definition":"Treatment of retroviral infections with medications that target the virus directly, limiting the ability of infected cells to produce new virus particles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49E7530B-6430-6451-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-04-02","modifiedBy":"TSESU","dateModified":"2023-01-04","changeDescription":"02/19/2015 - tc - Updated with NCIt concept.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C204-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"GENE TRANSFER","valueDescription":"Gene Therapy","ValueMeaning":{"publicId":"3082843","version":"1","preferredName":"Gene Therapy","longName":"3082843","preferredDefinition":"Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or an acquired disease such as cancer.  The genetic material as 'naked' DNA can be delivered into the cells alone or can be delivered into cells by different types of vectors such as viruses which may contain DNA or RNA.  Gene therapy techniques attempt to replace a faulty/missing gene associated with a particular disease, mediate localized delivery of a protein producing specified therapeutic effects, or introduce new cellular functions.  Gene therapies are designed to deliver genetic material into somatic cells and not germ cells, so that only cells of patients and not those of their offspring contain and express the genetic material delivered. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gene Therapy","conceptCode":"C15238","definition":"Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or acquired disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"85F4380C-67AF-77C6-E040-BB89AD4310D6","latestVersionIndicator":"Yes","beginDate":"2010-05-06","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2010-05-06","modifiedBy":"ONEDATA","dateModified":"2010-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C21B-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"BONE MARROW TRANSPLANTATION","valueDescription":"Bone Marrow Transplantation","ValueMeaning":{"publicId":"3021570","version":"1","preferredName":"Bone Marrow Transplantation","longName":"3021570","preferredDefinition":"A procedure to replace diseased or pathologic bone marrow with transplanted healthy bone marrow cells. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Marrow Transplantation","conceptCode":"C15194","definition":"A procedure to replace diseased bone marrow with transplanted healthy bone marrow cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"818DED3A-49AA-17D3-E040-BB89AD4304FC","latestVersionIndicator":"Yes","beginDate":"2010-03-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-11","modifiedBy":"TAYLORT","dateModified":"2020-05-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C227-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"MONOCLONAL ANTIBODIES","valueDescription":"Monoclonal Antibody","ValueMeaning":{"publicId":"4232285","version":"1","preferredName":"Monoclonal Antibody","longName":"4232285","preferredDefinition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Monoclonal Antibody","conceptCode":"C20401","definition":"An antibody produced by a clone or genetically homogenous fast-growing cells i.e., hybridoma. Hybridoma cells are cloned to establish cell lines producing a specific antibody that is chemically and immunologically homogeneous. They are widely used in cancer detection, diagnosis, and treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4E6DCBF-18CA-667F-E040-BB89AD431523","latestVersionIndicator":"Yes","beginDate":"2014-03-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C23C-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"IMMUNOTHERAPY","valueDescription":"Immunotherapy","ValueMeaning":{"publicId":"5102332","version":"1","preferredName":"Immunotherapy","longName":"5102332","preferredDefinition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunotherapy","conceptCode":"C15262","definition":"Therapy designed to induce changes in a patient's immune status in order to treat disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29400305-01FA-73D5-E050-BB89AD437D83","latestVersionIndicator":"Yes","beginDate":"2016-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-13","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C247-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"HORMONE THERAPY","valueDescription":"Endocrine Therapy","ValueMeaning":{"publicId":"4340414","version":"1","preferredName":"Endocrine Therapy","longName":"4340414","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAA223A1-46B7-E4F0-E040-BB89AD436356","latestVersionIndicator":"Yes","beginDate":"2014-05-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-05-30","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C253-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"CHEMOTHERAPY, NOS","valueDescription":"Chemotherapy, NOS","ValueMeaning":{"publicId":"2939754","version":"1","preferredName":"Chemotherapy, NOS","longName":"2939754","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04): Not characterized in any other way.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7351A664-1791-E6B7-E040-BB89AD430953","latestVersionIndicator":"Yes","beginDate":"2009-09-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-09-11","modifiedBy":"REEVESD","dateModified":"2009-09-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C25E-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"CHEMOTHERAPY, MULTIPLE AGENTS SYSTEMIC","valueDescription":"Chemotherapy multiple agents systemic","ValueMeaning":{"publicId":"5142772","version":"1","preferredName":"Chemotherapy multiple agents systemic","longName":"5142772","preferredDefinition":"Systemic chemotherapy with a multiple agent regimen. All routes of administration are acceptable as long as the regimen is intended for systemic therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Agent Systemic Chemotherapy","conceptCode":"C118618","definition":"Systemic chemotherapy with a multiple agent regimen. All routes of administration are acceptable as long as the regimen is intended for systemic therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CAF3096-9802-003C-E050-BB89AD4320A2","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C274-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"SINGLE AGENT SYSTEMIC CHEMOTHERAPY","valueDescription":"Single Agent Systemic Chemotherapy","ValueMeaning":{"publicId":"5142773","version":"1","preferredName":"Single Agent Systemic Chemotherapy","longName":"5142773","preferredDefinition":"Systemic chemotherapy with a single agent regimen. All routes of administration are acceptable as long as the agent is intended for systemic therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Single Agent Systemic Chemotherapy","conceptCode":"C15756","definition":"Systemic chemotherapy with a single agent regimen. All routes of administration are acceptable as long as the agent is intended for systemic therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CAF3096-9825-003C-E050-BB89AD4320A2","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C28A-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"OTHER","valueDescription":"Specify Other","ValueMeaning":{"publicId":"6782229","version":"1","preferredName":"Specify Other","longName":"6782229","preferredDefinition":"A directive to indicate a response not listed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specify Other","conceptCode":"C157106","definition":"A directive to indicate a response not listed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B4B4921-90A3-4044-E053-F662850ADEE5","latestVersionIndicator":"Yes","beginDate":"2019-06-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-14","modifiedBy":"TSESU","dateModified":"2022-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AA84C6A7-C295-382E-E053-4EBD850A5A7D","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"ONEDATA","dateModified":"2020-07-16","deletedIndicator":"No"},{"value":"KINASE INHIBITORS","valueDescription":"Kinase Inhibitor","ValueMeaning":{"publicId":"7313045","version":"1","preferredName":"Kinase Inhibitor","longName":"7313045","preferredDefinition":"Encoded by Kinase Family Genes, Kinase enzymes covalently transfer the terminal, gamma phosphate group from ATP to a variety of substrates and typically play key regulatory roles in diverse cellular functions. (NCI): A class of substances that binds to and inhibits the function or activity of a target.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kinase","conceptCode":"C28597","definition":"Encoded by Kinase Family Genes, Kinase enzymes covalently transfer the terminal, gamma phosphate group from ATP to a variety of substrates and typically play key regulatory roles in diverse cellular functions. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Inhibitor","conceptCode":"C154898","definition":"A class of substances that binds to and inhibits the function or activity of a target.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D46E89-CAC5-6F2D-E053-4EBD850A4773","latestVersionIndicator":"Yes","beginDate":"2020-05-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-05-30","modifiedBy":"ONEDATA","dateModified":"2020-05-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AAE49FF0-B160-09E2-E053-4EBD850A4F66","beginDate":"2020-07-20","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-20","modifiedBy":"ONEDATA","dateModified":"2020-07-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435019","version":"1","preferredName":"Conceptual Entity","preferredDefinition":"An organizational header for concepts representing mostly abstract entities.","longName":"C20181","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D8-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7185231","version":"1","preferredName":"Concomitant Medication Category Clinical Study Sponsor Defined Category","preferredDefinition":"A classification of concomitant medication data.:An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]:Clearly characterized or delimited.:A grouping of items based on some commonality or by user defined characteristics.","longName":"C83218:C70793:C165683:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Concomitant Medication Category","conceptCode":"C83218","definition":"A classification of concomitant medication data.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Clinical Study Sponsor","conceptCode":"C70793","definition":"An entity such as an individual, company, institution, group, or organization which takes responsibility for the initiation, management, and/or financing of a clinical study. The sponsor does not actually conduct the investigation unless the sponsor is a sponsor-investigator. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct research it has initiated is considered to be a sponsor, and the employees are considered to be investigators. [21 CFR P.50.3(k)] [21 CFR P.50.102(j)] [21 CFR P.312.3]","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Defined","conceptCode":"C165683","definition":"Clearly characterized or delimited.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F6876B1-BBA6-3D0C-E053-F662850AA045","latestVersionIndicator":"Yes","beginDate":"2020-02-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-02-25","modifiedBy":"ONEDATA","dateModified":"2020-02-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA84C6A7-C198-382E-E053-4EBD850A5A7D","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeDescription":"7-16-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"What is the category for the","type":"Preferred Question Text","description":"What is the category for the (concomitant) [medication/treatment/therapy]?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Therapy category","url":null,"context":"NRDS"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA83AA5F-0232-44F3-E053-4EBD850A893B","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"TAYLORT","dateCreated":"2020-07-16","modifiedBy":"SOKKERL","dateModified":"2021-08-04","changeDescription":"7-16-20 NCICOVID; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}